drugset / Trial / NCT05727397
Efficacy and Safety of RC28-E Versus Aflibercept
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.
Timeline
- Start
- 2023-03-14
- Primary completion
- 2025-11-29
- Completion
- 2025-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | RC28-E | Protein / enzyme biologic | 2 mg | Intravitreal |